Skip to main content
Premium Trial:

Request an Annual Quote

Ambry Becomes CSP for Roche NimbleGen Offerings

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Ambry Genetics has been named a certified service provider for several product offerings from Roche NimbleGen.

Aliso Viejo, Calif.-based Ambry will offer services using Nimblegen's comparative genomic hybridization, chromatin immunoprecipitation-on-chip, DNA methylation, and gene expression tools. The addition of these applications means that Ambry is now certified on all Roche NimbleGen applications, Roche said today.

Ambry will conduct copy number variation, DNA methylation analysis, gene expression analysis, and DNA-protein interactions and chromatin structure analysis using the NimbleGen products at its lab in California.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.